维普期刊资源整合服务平台（V6.5）

45篇 您的检索式：作者名="ESTEVA F J"

选中清除导出查看参考文献查看引证文献引用追踪共3页首页上一页第1页下一页末页 /3 跳转

	题名	作者	年代	出处	被引量
1	On the Standard and Rational Completeness of Some Axiomatic Extensions of the Monoidal t-norm Based Logic显示文摘	ESTEVA F GISPERT J GODO L	2002	Stud Logica2002，71，：	1
2	Recombinant human erythropoietin antagonizes trastuzurnab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inacti- vation显示文摘	Liang K Esteva F J Albarracin C	2010	Cancer Ce112010，18，5：	1
3	PTEN,PIK3CA,p-AKT,and p-p70S6K status:association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer显示文摘	Esteva F J Guo H Zhang S		0，，04：	1
4	Molecu- lar predictors of response to trastuzumab and lapatinib in breast eancer显示文摘	Esteva F J Yu D Hung M C Hortobagyi G N	2010	Nat Rev Clin Oneol2010，7，：	1
5	Defining prognosis for women with breast cancer and CNS metastases by HER2 status显示文摘	Dawood S Broglio K Esteva F J	2008	Ann Oncol2008，19，7：	1
6	CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5 - fluorouracil, epirubicin, and cyclophosphamide in HER - 2 - overexpressing breast cancer 显示文摘	Esteva FJ Wang J Lin F	2007	Breast Cancer Res2007，9，6：	1
7	Phase II study ofliposomalannamycin in the treatment of doxorubicin-resistant breast cancer显示文摘	Booser D J Esteva F J Rivera E	2002	Cancer Chemotherapy and Pharmacology2002，50，1：	1
8	Prognostic molecular markers in early breast cancer 显示文摘	Esteva F J Hortobagyi GN	2004	Breast Cancer Res2004，6，3：	1
9	Chemotherapy of metastatic breast cancer:what to expect in and beyond 显示文摘	ESTEVA F J VALERO V PYSZTAI L	2001	Oncol-ogist2001，6，2：	1
10	Herceptin:mechanisms of action and resistance显示文摘	NAHTA R ESTEVA F J	2006	Cancer Lett2006，232，2：	1
11	Phase Ⅱ trial of weekly docetaxel and trastuzumab for patients with HER2- overpressing metastatic breast cancer 显示文摘	Esteva F J Valero V Booser D	2002	J Clin Oncol2002，20，7：	1
12	Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer 显示文摘	DEAN-COLOMB W ESTEVA F J	2008	Semin Oncol2008，35，2：	1
13	Herceptin:mechanisms of action and resistance显示文摘	Nahta R Esteva F J	2006	Cancer Lett2006，232，2：	1
14	Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer显示文摘	GONZALEZ-ANGULO A M HORTOBAGYI G N ESTEVA F J	2006	Oncologist2006，11，8：	1
15	Survival among women with triple receptor-negative breast cancer and brain metastases 显示文摘	Dawood S Broglio K Esteva F J	2009	Ann Oncol2009，20，4：	1
16	Her2-positive breast cancer: herceptin and beyond显示文摘	Dean-Colomb W Esteva F J	2008	Eur J Cancer2008，44，18：	1
17	Safety and efficacy of bisphosphonates beyond 24 months in cancer patients 显示文摘	Esteva F J Hortobagyi G	2001	J Clin Oncol2001，19，：	1
18	0n the standard and rational completeness of some axiomatic extensions of the monoidal t- norm based ligic显示文摘	Esteva F Gispert J Godo L	2002	Stud Logica2002，71，：	1
19	PTEN PIK3 CA p-Akt and p- p70S6K status association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer显示文摘	Esteva F J Guo H Zhang S	2010	Am J Pathol2010，177，4：	1
20	Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification显示文摘	SEIDMAN A D FORNIER M N ESTEVA F J	2001	J Clin Oncol2001，19，10：	1

返回顶部每页显示：

共3页首页上一页第1页下一页末页 /3 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示